PromarkerD and PromarkerEso Commercial Rollout Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has announced the controlled market release of Promarker®D and Promarker®Eso in Western Australia and the Northern Territory under a distribution agreement with Healius Limited. The company expects broader commercial sales to follow, pending successful implementation activities, with initial pricing set for the tests. This update marks a significant step in the national rollout of the Promarker product portfolio, leveraging Healius' extensive collection network.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Appendix 4E and Annual Report
- Appendix 4G and Corporate Governance Statement
- Australian patent for PromarkerEndo
- Change in substantial holding
- Proteomics signs national distribution deal with Healius
Later from Proteomics International Laboratories
- Investor Presentation
- Notice of AGM Date
- PromarkerEndo Validation and Refinement Complete
- Ignite Investment Summit Presentation
- Proteomics International receives $2.0m in R&D tax incentive
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories